# Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia

> **NCT01338298** · NA · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 60 (actual)

## Conditions studied

- Hyperprolactinemia

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01338298
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01338298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01338298, "Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01338298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*